<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072213</url>
  </required_header>
  <id_info>
    <org_study_id>GL2702-103</org_study_id>
    <nct_id>NCT02072213</nct_id>
  </id_info>
  <brief_title>A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Four-sequence, Four -Period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GL Pharm Tech Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male
      Volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GL2702 GLARS-NF1 tablet is controlled released formulation which is invented by GL Pharm Tech
      Corp.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48h</time_frame>
    <description>Pharmacokinetic parameter of tamsulosin 0.4mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>48h</time_frame>
    <description>Pharmacokinetic parameter of Tamsulosin 0.4mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>48h</time_frame>
    <description>Pharmacokinetic parameter of Tamsulosin 0.4 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>48h</time_frame>
    <description>Pharmacokinetic parameter of Tamsulosin 0.4 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>48h</time_frame>
    <description>Pharmacokinetic parameter of Tamsulosin 0.4 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>48h</time_frame>
    <description>Pharmacokinetic parameter of Tamsulosin 0.4 mg</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GL2702 GLARS-NF1 , fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulsoin 0.4mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omix Ocas® , fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulsoin 0.4mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GL2702 GLARS-NF1, after meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulsoin 0.4mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omix Ocas®, after meal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulsoin 0.4mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GL2702 GLARS-NF1</intervention_name>
    <description>0.4mg once a day</description>
    <arm_group_label>GL2702 GLARS-NF1 , fasted</arm_group_label>
    <arm_group_label>GL2702 GLARS-NF1, after meal</arm_group_label>
    <other_name>Tamsulosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omix Ocas</intervention_name>
    <description>0.4mg once a day</description>
    <arm_group_label>Omix Ocas® , fasted</arm_group_label>
    <arm_group_label>Omix Ocas®, after meal</arm_group_label>
    <other_name>Tamsulosin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20~45 years old, Healthy Adult Male Subject

          -  Body Weight ≥ 50kg and Ideal Body Weight ≤ ±20%

        Exclusion Criteria:

          -  ALT or AST &gt; 1.25 times (Upper Normal Range)

          -  Total Bilirubin &gt; 1.5 times (Upper Normal Range)

          -  CPK &gt; 2 times (Upper Normal Range)

          -  BUN or Creatinine &gt; Normal Range

          -  Systolic BP &gt; 160mmHg or &lt; 80mmHg, Diastolic BP &gt; 100mmHg or &lt; 50mmHg
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabukdo</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tamsulosin,controlled release formulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

